Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
PATIENT INCLUSION CRITERIA:~* Male or female and aged 18 years or over;~* Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Autonomic Neuropathies;~* A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing;~* Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.~MAIN PATIENT EXCLUSION CRITERIA:~* Taking ephedrine or midodrine; Patients taking ephedrine or midodrine may enroll after a minimum 7 day washout period;~* Taking anti-hypertensive medication;~* Have a history of more than moderate alcohol consumption;~* Women who are pregnant or lactating;~* Have a history of closed angle glaucoma;~* Have pre-existing sustained severe hypertension (BP \> 180/110 mmHg in the sitting position);~* Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia;~* In the investigator's opinion, have any other significant systemic, hepatic, cardiac or renal illness;~* Have diabetes mellitus or insipidus;~* Have a known or suspected malignancy;~* Have known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug;~* In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing;~* Have a serum creatinine level \> 130 µmol/L;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Droxidopa (Type: EXPERIMENTAL): Double-blind
- Placebo (Type: PLACEBO_COMPARATOR): Double-blind

Based on this trial design, predict the completion outcome and termination type (if applicable).